APOBEC3A and endometrial cancer: Applying individual models, not adjusted for multiple models, we found the APOBEC3A/B deletion variant to be significantly associated with reduced risk for endometrial cancer, applying both the dominant‐ and the allele‐models (OR = 0.75; 95% CI = 0.62–0.91; p = 0.003, OR = 0.75; 95% CI = 0.63–0.90; p = 0.0002, respectively; Figure 1, Table S2).